SCHEMBL120242

SCHEMBL120242

CC(C)(C)OC(=O)N1CC(NC(=O)c2ccccc2)C1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 6/20 0.64
KDM4E B2RXH2 1/20 0.57
PKM P14618 1/20 0.57
GABRA5 P31644 1/20 0.52
NR1H2 P55055 1/20 0.51
RORC P51449 1/20 0.50
POLR1A O95602 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
HDAC4 P56524 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
CCR8 P51685 1/20 0.48
CHRM1 P11229 1/20 0.48
NAMPT P43490 1/20 0.48
POLB P06746 1/20 0.47
MMP2 P08253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121519 0.91 USP30 (0.59) USP30KDM4EPKMGABRA5NR1H2
SCHEMBL994594 0.90 USP30 (0.71) USP30KDM4EPKMMEN1KMT2A
SCHEMBL4921150 0.90 USP30 (0.71) USP30KDM4EPKMMEN1KMT2A
SCHEMBL4924196 0.90 USP30 (0.71) USP30KDM4EPKMMEN1KMT2A
SCHEMBL5145035 0.87 USP30 (0.82) USP30KDM4EPKMGABRA5MEN1
SCHEMBL15706793 0.86 USP30 (0.54) USP30GABRA5NR1H2POLR1AKMT2A
SCHEMBL13199301 0.86 KDM4E (0.68) USP30KDM4EPKMMEN1KMT2A
SCHEMBL12338348 0.86 KDM4E (0.58) USP30KDM4EPKMGABRA5RORC
SCHEMBL22131008 0.86 USP30 (0.77) USP30KDM4EPKMGABRA5MEN1
SCHEMBL13175930 0.85 USP30 (0.60) USP30KDM4EPKMGABRA5NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759333-B2 Di-azetidinyl diamide as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-8759533-B2 Di-azetidinyl diamide as monoacylglcerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20130196969-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20130196968-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
WO-2012030907-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-03-08 WO disclosed
US-20120058986-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196969-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS MGLL, PNLIP, LPL USP30 509/4885KDM4E 2642/4885PKM 4024/4885
US-20130196968-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS MGLL, PNLIP, LPL USP30 509/4885KDM4E 2642/4885PKM 4024/4885
US-20120058986-A1 DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA USP30 293/4885KDM4E 1848/4885PKM 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.